Cable Hill Partners’s ImmunityBio IBRX Stock Holding History

Cable Hill Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,000	Closed	-$16K	–	386
2019 Q1	$16K	Buy	+10,000	New	+$12.6K	0.01%	414

Other funds holding IBRX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cable Hill Partners's IBRX Position: Q2 2019 in Review

Cable Hill Partners sold out of ImmunityBio (IBRX) in Q2 2019, closing a stake of 10,000 shares — an estimated $16K sold.

Cable Hill Partners first reported a position in IBRX in Q1 2019 and held it in 1 quarter. The position peaked at $16K in Q1 2019. 47 funds tracked by Wall St. Rank hold IBRX as of Q2 2019.

Cable Hill Partners reported no remaining ImmunityBio position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 10,000 ImmunityBio shares in Q2 2019, an estimated $16K.
Cable Hill Partners first reported a position in ImmunityBio in Q1 2019 and held it in 1 quarter.
Cable Hill Partners's ImmunityBio position peaked at $16K in Q1 2019.
47 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.